Clinical trials: Cushing's Disease
Cushings Disease
Treatment of Cushing's Disease With R-roscovitine
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
- Trial name
- NCT02160730
- Testing
- R-roscovitine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shlomo Melmed, MD
Cushing Syndrome, Cushing Disease
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an…
- Conditions
- Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
- Trial name
- NCT05804669
- Testing
- atumelnant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori